<DOC>
	<DOCNO>NCT02594865</DOCNO>
	<brief_summary>To investigate whether administration Glucerna achieve less glycaemic variability , define mean absolute glucose ( MAG ) change , good glycaemic control compare standard high-carbohydrate enteral formula . Continuous glucose monitoring technology use evaluate glycaemic variability glycaemic control .</brief_summary>
	<brief_title>The Glycaemic Effects Glucerna® Critically Ill Patients .</brief_title>
	<detailed_description />
	<mesh_term>Critical Illness</mesh_term>
	<criteria>Age ≥ 18 year ; Patients anticipate stay least 48 hour admission intensive care Expected receive enteral feeding least 48 hrs Indication glucose regulation insulin ( accord current glucose treatment protocol ) Patient surrogate understand sign informed consent document . Patients preexist contraindication enteral feed placement continuous glucose monitoring system Patients previously randomise GluCip trial Any disease condition investigator treat physician feel would interfere trial safety patient .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Enteral Nutrition</keyword>
	<keyword>Continuous Glucose Monitoring</keyword>
</DOC>